Jove
Visualize
Contact Us

Related Experiment Videos

Update on hormone-refractory prostate cancer.

Karl M Kasamon1, Nancy A Dawson

  • 1Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.

Current Opinion in Urology
|April 8, 2004
PubMed
Summary

Hormone-refractory prostate cancer management is evolving. Novel therapies, including bisphosphonates and chemotherapy, offer improved palliative care and survival outcomes for advanced prostate cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer.

Cureus·2026
Same author

Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.

BMC cancer·2025
Same author

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.

Frontiers in oncology·2025
Same author

Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy.

Frontiers in oncology·2025
Same author

The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue.

Frontiers in oncology·2024
Same author

Impact of neoadjuvant relugolix on patient-reported sexual function and bother.

Frontiers in oncology·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Androgen deprivation therapy (ADT) is standard for metastatic prostate cancer.
  • Most patients eventually develop hormone-refractory prostate cancer (HRPC).
  • HRPC presents significant clinical management challenges.

Purpose of the Study:

  • This review focuses on the management of hormone-refractory prostate cancer.
  • To explore recent advancements in treating advanced prostate cancer.

Main Methods:

  • Review of current literature on HRPC.
  • Analysis of emerging therapeutic strategies and prognostic tools.

Main Results:

  • Bisphosphonates and chemotherapy provide effective palliative care.

Related Experiment Videos

  • Taxane-based regimens show promising response rates and survival in Phase II trials.
  • New prognostic tools are enhancing patient outcome prediction.

    • Conclusions:

    • Advancements in understanding HRPC pathophysiology are improving treatment.
    • Chemotherapy and novel agents are expanding therapeutic options for HRPC.
    • Ongoing Phase III trials will clarify the survival benefits of current chemotherapy regimens.